Health Without Borders
We live in a world where human, animal, plant and environmental health are intrinsically connected. A crop disease can threaten food security, livestock infections can impact animal welfare and health and disrupt trade and livelihoods, and environmental change can create new opportunities for disease emergence and spread. At the same time, growing resistance to antimicrobials and antiparasitic treatments is reducing the effectiveness of some of our most valuable disease-control tools.
Yet despite significant advances in diagnostic technology, many of the tools capable of supporting earlier detection and targeted interventions remain inaccessible, unaffordable or unavailable where decisions need to be made. The greatest barrier to progress may no longer be innovation, but implementation.
If disease does not respect boundaries, our diagnostic solutions cannot afford to either.
From Detection to Better Decisions
The true value of diagnostics lies not only in detecting disease, but in enabling better decisions. Across the One Health landscape, rapid and accessible testing can help shift disease management from reactive intervention to proactive prevention.
On farms, diagnostics can support the targeted use of interventions by identifying infection before clinical signs become widespread, reducing unnecessary treatment and helping to slow the emergence of resistance. In livestock, rapid tests can help monitor diseases and parasites such as liver fluke, enabling treatment only when needed rather than relying on routine prophylactic dosing. In crop production, diagnostics can help identify pathogen risk and disease pressure early, allowing growers to make more informed management decisions while reducing waste and spoilage. Similar approaches are also becoming increasingly important for the surveillance of transboundary animal diseases such as foot-and-mouth disease and lumpy skin disease, alongside emerging zoonotic threats including highly pathogenic avian influenza and Nipah virus, where early detection can be critical in limiting spread and protecting both animal and human health.
Whether supporting food security, disease surveillance, antimicrobial stewardship or outbreak preparedness, diagnostics place actionable information directly into the hands of those making decisions. However, their value is only realised when they are affordable, accessible and deployable at the point of need. Bridging the gap between technological capability and routine adoption remains one of the greatest opportunities to strengthen One Health outcomes.
The Cost of a Missed Diagnosis
Every delayed or missed diagnosis represents a lost opportunity to intervene early, contain disease, protect animal welfare, safeguard food production and reduce unnecessary treatment. Whether responding to a crop pathogen, managing parasitic infection in livestock, monitoring emerging zoonotic threats or strengthening outbreak preparedness, timely access to reliable and affordable diagnostic information enables faster, targeted and more sustainable action.
Diagnostics and Antimicrobial Resistance
This is particularly important in the fight against antimicrobial resistance (AMR), where diagnostics can help ensure that the correct treatments are used only when needed and where they are most likely to be effective. The consequences of resistance are felt across the One Health spectrum. Drug-resistant bovine tuberculosis (Mycobacterium bovis), a zoonotic pathogen that remains a significant challenge in many parts of Africa, highlights the complex links between animal and human health. Likewise, the emergence of triclabendazole-resistant liver fluke parasite highlights the interconnected nature of One Health, reducing the effectiveness of a treatment relied upon to control fascioliasis in both animals and humans.
The Growing Threat of Fungal Pathogens
Fungal pathogens provide another stark example. Reported to be responsible for more than a billion human infections and over 1.6 million deaths globally each year, they pose an increasing threat to both agriculture and public health. Growing resistance to azoles is particularly concerning, as related compounds are relied upon both to protect crops and to treat serious fungal infections in humans.
From Innovation to Implementation
However, a technically excellent diagnostic is only valuable if people use it. Adoption depends on clear economic value, regulatory or societal drivers, whether that is reducing losses, improving productivity, supporting antimicrobial stewardship, meeting certification requirements or strengthening disease surveillance. As disease pressures intensify through globalisation, climate change and increasing antimicrobial resistance, diagnostics must become as affordable, accessible and deployable as the threats they are designed to detect.
Disease doesn’t wait. Neither can our ability to turn diagnostic innovation into real-world impact.
Work with GADx
Accelerating One Health diagnostics together
We’re keen to collaborate with researchers, funders, commercial partners and innovators working to accelerate the development and implementation of accessible diagnostic solutions across the One Health landscape.
References
- Genetic diversities and drug resistance in Mycobacterium bovis isolates from zoonotic tuberculosis using whole genome sequencing | BMC Genomics
- Meta-analysis of the prevalence of tuberculosis in cattle and zoonotic tuberculosis in humans in sub-Saharan Africa | One Health Outlook
- Molecular epidemiology and whole genome sequencing analysis of clinical Mycobacterium bovis from Ghana | PLOS One
- Trends of Mycobacterium bovis Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance | PLOS Neglected Tropical Diseases
- Independent origins and non-parallel selection signatures of triclabendazole resistance in Fasciola hepatica | Nature Communications
- WHO identifies 4 critically important fungi causing millions of deaths a year | Fungal Infection Trust
- Deadly Fungi Are the Newest Emerging Microbe Threat All Over the World | Scientific American
- European Commission AMR document (April 2026)
- Azole fungicides and Aspergillus resistance: five EU agency report highlights the problem for the first time using a One Health approach | npj Antimicrobials and Resistance
- The dual role of azoles: lifesaving antifungals and drivers of resistance – a One Health perspective | Nature Communications
- Inside Health – Is a fungal pandemic possible? | BBC Sounds
